TY - JOUR
T1 - Small bowel capsule endoscopy in refractory celiac disease
T2 - A luxury or a necessity?
AU - Zammit, Stefania Chetcuti
AU - Elli, Luca
AU - Scaramella, Lucia
AU - Sanders, David S.
AU - Tontini, Gian Eugenio
AU - Sidhu, Reena
N1 - Publisher Copyright:
© 2021 Hellenic Society of Gastroenterology.
PY - 2021
Y1 - 2021
N2 - Background Small bowel capsule endoscopy (SBCE) has an established role in the management of refractory celiac disease (RCD) for the detection of complications. The aim of this study was to define the role of SBCE in the management of patients with RCD. Method Patients with histologically confirmed RCD who underwent successive SBCEs were recruited retrospectively from 2 tertiary centers. Results Sixty patients with RCD were included. The percentage extent of the affected small bowel (SB) mucosa improved on repeating a second SBCE in 26 patients (49.1%) (median 27.6% vs. 18.1%, P=0.007). Patients with RCD type II had more extensive disease than those with RCD type I on first (41.4% vs. 19.2%, P=0.004) and second (29.8% vs. 12.0%, P=0.016) SBCE. Patients with RCD type I tended to show a greater improvement in percentage of abnormal SB involved on repeat SBCE compared to those with RCD type II (P=0.049). Nine patients (15%) had RCD-related complications. Five patients developed ulcerative jejunoileitis, 3 patients developed enteropathy-associated T-cell lymphoma, and 1 patient developed cutaneous T-cell lymphoma. Conclusions SBCE can be a useful tool for monitoring the effects of treatment, primarily following its initiation. Patients with RCD type II have more extensive SB disease, equating to a more aggressive disease pattern.
AB - Background Small bowel capsule endoscopy (SBCE) has an established role in the management of refractory celiac disease (RCD) for the detection of complications. The aim of this study was to define the role of SBCE in the management of patients with RCD. Method Patients with histologically confirmed RCD who underwent successive SBCEs were recruited retrospectively from 2 tertiary centers. Results Sixty patients with RCD were included. The percentage extent of the affected small bowel (SB) mucosa improved on repeating a second SBCE in 26 patients (49.1%) (median 27.6% vs. 18.1%, P=0.007). Patients with RCD type II had more extensive disease than those with RCD type I on first (41.4% vs. 19.2%, P=0.004) and second (29.8% vs. 12.0%, P=0.016) SBCE. Patients with RCD type I tended to show a greater improvement in percentage of abnormal SB involved on repeat SBCE compared to those with RCD type II (P=0.049). Nine patients (15%) had RCD-related complications. Five patients developed ulcerative jejunoileitis, 3 patients developed enteropathy-associated T-cell lymphoma, and 1 patient developed cutaneous T-cell lymphoma. Conclusions SBCE can be a useful tool for monitoring the effects of treatment, primarily following its initiation. Patients with RCD type II have more extensive SB disease, equating to a more aggressive disease pattern.
KW - Celiac disease
KW - Extent of disease
KW - Refractory celiac disease
KW - Small bowel capsule endoscopy
UR - http://www.scopus.com/inward/record.url?scp=85103030827&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103030827&partnerID=8YFLogxK
U2 - 10.20524/aog.2021.0586
DO - 10.20524/aog.2021.0586
M3 - Article
AN - SCOPUS:85103030827
VL - 34
SP - 188
EP - 195
JO - Annals of Gastroenterology
JF - Annals of Gastroenterology
SN - 1108-7471
IS - 2
ER -